Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, 16766 Jingshi Road, Jinan, 250014, Shandong, China.
Eur Radiol. 2023 Feb;33(2):1112-1120. doi: 10.1007/s00330-022-09129-z. Epub 2022 Sep 22.
A drug-coated balloon (DCB) has potential applications in the treatment of intracranial atherosclerotic disease (ICAD). We aimed to evaluate changes of vessel wall features of ICAD lesions after DCB treatment by using vessel wall MRI (VWMRI).
We retrospectively included patients with symptomatic ICAD who underwent DCB angioplasty alone. The incidences of stenosis of the lumen area, vessel wall thickening, hyperintense plaques, and prominent wall enhancement were compared between the baseline and follow-up VWMRI.
There were 29 ICAD lesions from 29 patients, of which 22 were stenosis and 7 were occlusion. The median interval between DCB treatment and follow-up VWMRI was 4.1 [3.3, 6.7] months. After DCB treatment, follow-up VWMRI showed a significant decrease in the stenosis degree of the lumen area (83% [71%, 96%] vs 15% [3%, 41%], p < 0.001). Thirty-eight percent (11/29) of the patients observed normal appearance of the target vessel wall on follow-up VWMRI. In the stenosis group, the prevalence of hyperintense plaques decreased from 66.7% (14/21) at baseline to 23.8% (5/21) at follow-up, and prominent wall enhancement decreased from 66.7% (14/21) at baseline to 19.0%(4/21) at follow-up. The incidence of hyperintense plaques (p = 0.028) and vessel wall thickening (p = 0.018) tended to decrease with follow-up time. Although not significant (p = 0.106), a similar trend was observed between the incidence of prominent wall enhancement and follow-up time.
Vascular healing with plaque modification and stabilization occurred following DCB treatment of ICAD lesions.
• A drug-coated balloon (DCB) has potential applications in the treatment of intracranial atherosclerotic disease (ICAD). • Vascular healing with plaque modification and stabilization occurred following DCB treatment of ICAD lesions.
药物涂层球囊(DCB)在颅内动脉粥样硬化性疾病(ICAD)的治疗中有应用潜力。我们旨在通过血管壁 MRI(VWMRI)评估 DCB 治疗后 ICAD 病变血管壁特征的变化。
我们回顾性纳入了单独接受 DCB 血管成形术治疗的有症状性 ICAD 患者。比较了基线和随访 VWMRI 时管腔面积狭窄、血管壁增厚、高信号斑块和明显壁强化的发生率。
29 例患者的 29 处 ICAD 病变中,22 处为狭窄,7 处为闭塞。DCB 治疗与随访 VWMRI 之间的中位时间间隔为 4.1[3.3,6.7]个月。DCB 治疗后,随访 VWMRI 显示管腔面积狭窄程度显著降低(83%[71%,96%] vs 15%[3%,41%],p<0.001)。38%(11/29)的患者在随访 VWMRI 时观察到目标血管壁正常外观。在狭窄组中,高信号斑块的患病率从基线时的 66.7%(14/21)降至随访时的 23.8%(5/21),明显壁强化从基线时的 66.7%(14/21)降至随访时的 19.0%(4/21)。高信号斑块的发生率(p=0.028)和血管壁增厚(p=0.018)随随访时间呈下降趋势。虽然不显著(p=0.106),但明显壁强化的发生率与随访时间之间也存在类似趋势。
DCB 治疗 ICAD 病变后,发生了血管愈合、斑块修饰和稳定。
药物涂层球囊(DCB)在颅内动脉粥样硬化性疾病(ICAD)的治疗中有应用潜力。
DCB 治疗 ICAD 病变后,发生了血管愈合、斑块修饰和稳定。